The bill S.106 aims to extend the tenure of the Psychedelic Therapy Advisory Working Group, which was originally established by Act and Resolves No. 126 in 2024. The Working Group is tasked with reviewing research on the cost-benefit profile of psychedelics for mental health improvement and making recommendations regarding a state program for healthcare providers to administer psychedelics in therapeutic settings. The bill proposes to expand the membership of the Working Group to include additional experts and stakeholders, thereby enhancing its capacity to monitor evolving research and programs related to psychedelic therapies in Vermont.

Key provisions of the bill include the continuation of the Working Group's review of public health benefits and risks associated with clinical psychedelic treatments, monitoring laws and programs in other states, and proposing a pilot project for psilocybin-assisted therapies for individuals with serious illnesses. The Working Group is required to submit a report with findings and recommendations by November 15, 2025, and will be supported by the Vermont Department of Mental Health. The bill also specifies that the Working Group will cease to exist on January 1, 2026, and it will take effect upon passage.